Robert Howard, Rupert McShane, James Lindesay, Craig Ritchie et al.
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease. METHODS: We assigned 295 community-dwelling patients wh...
Olivia Anna Skrobot, Sandra E. Black, Christopher Chen, Charles DeCarli et al.
INTRODUCTION: Progress in understanding and management of vascular cognitive impairment (VCI) has been hampered by lack of consensus on diagnosis, reflecting the use of multiple different assessment protocols. A large multinational group of clinicians and researchers participated in a two-phase Vasc...
Wei Bai, Pan Chen, Hong Cai, Qinge Zhang et al.
BACKGROUND: Mild cognitive impairment (MCI) is the preclinical and transitional stage between healthy ageing and dementia that may be a potential 'target' for interventions designed to delay progression to dementia. In this systematic review and meta-analysis, we assessed the prevalence of MCI world...
Sabine Ring, Sascha W. Weyer, Susanne B. Kilian, Elaine Waldron et al.
It is well established that the proteolytic processing of the beta-amyloid precursor protein (APP) generates beta-amyloid (Abeta), which plays a central role in the pathogenesis of Alzheimer's disease (AD). In contrast, the physiological role of APP and of its numerous proteolytic fragments and the ...
Joseph Butchart, Laura Brook, Vivienne Hopkins, Jessica L. Teeling et al.
OBJECTIVES: To determine whether the tumor necrosis factor α inhibitor etanercept is well tolerated and obtain preliminary data on its safety in Alzheimer disease dementia. METHODS: In a double-blind study, patients with mild to moderate Alzheimer disease dementia were randomized (1:1) to subcutaneo...
Margaret May, Peter McCarron, Stephen Stansfeld, Yoav Ben‐Shlomo et al.
BACKGROUND AND PURPOSE: Psychological distress is common after stroke, but little is known about its etiologic importance, although the general public often ascribes stroke to the experience of stress. Therefore, we examined whether psychological distress leads to an increased risk of ischemic strok...
F. M. Javed Mehedi Shamrat, Shamima Akter, Sami Azam, Asif Karim et al.
Alzheimer’s disease is largely the underlying cause of dementia due to its progressive neurodegenerative nature among the elderly. The disease can be divided into five stages: Subjective Memory Concern (SMC), Mild Cognitive Impairment (MCI), Early MCI (EMCI), Late MCI (LMCI), and Alzheimer’s Disease...
Siti Maisarah Mattap, Devi Mohan, Andrea McGrattan, Pascale Allotey et al.
INTRODUCTION: More than two-thirds of people with dementia live in low- and middle-income countries (LMICs), resulting in a significant economic burden in these settings. In this systematic review, we consolidate the existing evidence on the cost of dementia in LMICs. METHODS: Six databases were sea...
Morshedul Bari Antor, Ashfaq Jamil, Maliha Mamtaz, Mohammad Monirujjaman Khan et al.
Alzheimer's disease has been one of the major concerns recently. Around 45 million people are suffering from this disease. Alzheimer's is a degenerative brain disease with an unspecified cause and pathogenesis which primarily affects older people. The main cause of Alzheimer's disease is Dementia, w...
Charlotte E. Teunissen, Naura Elias, Marleen J.A. Koel‐Simmelink, Sisi Durieux‐Lu et al.
INTRODUCTION: Reliable cerebrospinal fluid (CSF) biomarkers enabling identification of frontotemporal dementia (FTD) and its pathologic subtypes are lacking. METHODS: Unbiased high-resolution mass spectrometry-based proteomics was applied on CSF of FTD patients with TAR DNA-binding protein 43 (TDP-4...
Ying Cui, Yun Jiao, Hua‐Jun Chen, Jie Ding et al.
OBJECTIVES: Type 2 diabetes mellitus is associated with increased risk for dementia. Patients with impaired cognition often show default-mode network disruption. We aimed to investigate the integrity of a default-mode network in diabetic patients by using independent component analysis, and to explo...
Juan Carlos Ruiz, Mufti Mahmud, Md Modasshir, M. Shamim Kaiser et al.
Robert W. Hopkins, Lindy A. Kilik, Duncan J. A. Day, Catherine P. Rows et al.
BACKGROUND: The population is becoming increasingly aged, and concomitantly, the prevalence of dementia is steadily rising. Persons aged 65 years and over are likely to continue driving for many years and often well into the dementia process. METHODS: Ontario Ministry of Transportation driving data,...
Afroza Rahman, Md. Anwar Hossen, Mirza Farhana Iqbal Chowdhury, Sadia Bari et al.
Aducanumab is a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trial...
Ketil Oppedal, Daniel Ferreira, Lena Cavallin, Afina W. Lemstra et al.
INTRODUCTION: We explored regional brain atrophy patterns and their clinical correlates in dementia with Lewy bodies (DLB). METHODS: In this multicentre study, we included a total of 333 patients with DLB, 352 patients with Alzheimer's disease (AD), and 233 normal controls and used medial temporal l...